Collaborations During the Pandemic: Issues and Tips When Considering Partnerships

Companies are scrambling to collaborate on the rapid development and deployment of products and services to address the pandemic. This requires highly-efficient dealmaking that enables important projects to quickly proceed, but also must account for unusual challenges in obtaining access to highly sought-after patient samples; disruptions to R&D based on stay-home orders, supply chain limitations, and other practical constraints; and an evolving regulatory landscape for vaccines, therapeutics and devices. This all must be balanced with the range of issues important in any biotech collaboration, such as the management of intellectual property and access to sufficient financial resources. This session will provide guidance and tips to consider in navigating this challenging time, which nonetheless presents tremendous opportunity for innovation.